The purpose of this grant application is to support Mayo Clinic membership in the Eastern Cooperative Oncology Group (ECOG). The goals are directed toward a greater understanding of cancer, a better understanding of cancer-related problems, development of improved cancer treatment programs, and improved cancer-patient survival. Mayo Clinic has the resources, personnel, facilities, a patient population to facilitate strong contributions to the research programs of the Eastern Cooperative Oncology Group. With the continued growth and development of the Mayo medical practice, we would anticipate significant protocol entry and scientific contribution. The ECOG affiliation and treatment program which have evolved provide major benefits to Mayo Clinic, its investigators, regional cancer programs, and the large group of cancer patients who are involved in these research activities.
The specific aims of this grant proposal are to support the following aspects of Mayo Clinic ECOG research activities including: 1. Patient accrual to group-wide ECOG cancer treatment protocols. 2. The evaluation of new protocol design and treatment regimens to provide group-wide ECOG Phase II and II cancer treatment protocols. 3. Coordination of, and participation in, adjunctive laboratory-based correlative studies in association with ECOG cancer treatment protocols. 4. Participation in disease-specific activities and such administrative roles as might be appointed and appropriate.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA013650-31
Application #
6632945
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2004-04-30
Budget Start
2003-05-01
Budget End
2004-04-30
Support Year
31
Fiscal Year
2003
Total Cost
$233,272
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Partridge, Ann H; Sepucha, Karen; O'Neill, Anne et al. (2017) Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? Breast Cancer Res Treat 165:545-553
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295
Vaz-Luis, Ines; O'Neill, Anne; Sepucha, Karen et al. (2017) Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 123:2821-2828
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004

Showing the most recent 10 out of 159 publications